Position in RGNX
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$270,831
+$170,973 QoQ
Shares Held
22,607
+118.5% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#91
of 163 holders
Holding Since
Sep 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RGNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $104,909,103 across 164 Biotechnology names. RGNX ranks #115 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IOVA |
Iovance Biotherapeutics, Inc.
|
655,318 | $2,726,122 | |
| 2 | IMVT |
Immunovant, Inc.
|
65,267 | $2,514,737 | |
| 3 | GOSS |
Gossamer Bio, Inc.
|
14,986,947 | $2,472,846 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
9,419 | $2,305,488 | |
| 5 | CABA |
Cabaletta Bio, Inc.
|
668,563 | $2,079,230 | |
| 6 | MLTX |
MoonLake Immunotherapeutics
|
106,695 | $2,077,351 | |
| 7 | ATYR |
aTYR PHARMA INC
|
3,454,863 | $2,062,553 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
23,257 | $2,022,196 |
All Filings in RGNX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $270,831 | 22,607 | Shares | Sole | 2026-08-06 | |
| 2025-09-30 | $99,858 | 10,348 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $1,860,238 | 226,582 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $939,002 | 131,329 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $133,620 | 17,286 | Shares | Sole | 2025-02-07 | |
| 2024-06-30 | $1,775,510 | 151,753 | Shares | Sole | 2024-08-15 | |
| 2023-09-30 | $620,015 | 37,668 | Shares | Sole | 2023-11-15 | |
| 2022-03-31 | $364,094 | 10,970 | Shares | Sole | 2022-05-11 | |
| 2021-09-30 | $286,104 | 6,825 | Shares | Sole | 2021-11-12 | |
| No filing history on record for this holder in this stock. | ||||||